Global Ocular Inflammation Treatment Market 2019-2023
About this market
The technological advances in drug delivery to push growth in the market. The increasing need for novel drug delivery systems has led to the advent of intravitreal implants, which are small hair-stranded sized devices that are implanted into the middle layer of the eye. Technavio’s analysts have predicted that the ocular inflammation treatment market will register a CAGR of more than 6% by 2023.
Growing awareness of eye care
Several organizations are conducting awareness campaigns on various eye-related diseases. Thus, the rising awareness about eye related diseases, including ocular inflammation is expected to contribute to the market growth during the forecast period.
Growing preference for surgeries
The global ocular inflammation market poses high threat from alternative treatment options such as non-invasive surgeries such as LASER treatments and invasive surgeries such as vitrectomy.
For the detailed list of factors that will drive and challenge the growth of the ocular inflammation treatment market during the 2019-2023, view our report.
The market appears to be concentrated and with the presence of several companies including AbbVie and Bausch Health the competitive environment is quite intense. Factors such as the growing awareness of eye care and the technological advances in drug delivery, will provide considerable growth opportunities to ocular inflammation treatment manufactures. AbbVie, Bausch Health, Novartis, and Pfizer are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be concentrated and with few companies constantly focusing to improve their market positions, the competitive environment among the players is quite intense’
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook